6 hasil untuk "Ingrid M Leal-Rojas"

Human cDC1 enhance cytotoxic function of CD226+ terminally exhausted tumor-infiltrating lymphocytes

Liam O’Brien; Irina Buckle; Ingrid M. Leal-Rojas dkk.

OncoImmunology, Vol. 14 No. 1 · 2025 · Inggris · DOAJ Scopus

Prevention or reversal of T cell exhaustion is a major objective of cancer immunotherapy. However, few models exist to generate, characterize and modulate exhausted human T cells, particularly within solid tumors in vivo, which likely hampers the discovery and translation of novel therapeutics. In…

Human Blood CD1c+ Dendritic Cells Promote Th1 and Th17 Effector Function in Memory CD4+ T Cells

Ingrid M. Leal Rojas; Wai-Hong Mok; Frances E. Pearson dkk.

Frontiers in Immunology, Vol. 8 · 2017 · Inggris · DOAJ Scopus

Dendritic cells (DC) initiate the differentiation of CD4+ helper T cells into effector cells including Th1 and Th17 responses that play an important role in inflammation and autoimmune disease pathogenesis. In mice, Th1 and Th17 responses are regulated by different conventional (c) DC subsets, with…

Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model

Victoria Atkinson; Kelly-Anne Masterman; Ingrid M Leal-Rojas dkk.

Journal for ImmunoTherapy of Cancer, Vol. 9 No. 3 · 2021 · Inggris · DOAJ Scopus

Background The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of immune checkpoint inhibitor (ICI) therapies in animal models but little is known about the role of the human CD141+ DC cDC1 equivalent in patients with melanoma.Methods We…

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells

Kelly-Anne Masterman; Oscar L Haigh; Kirsteen M Tullett dkk.

Journal for ImmunoTherapy of Cancer, Vol. 8 No. 2 · 2020 · Inggris · DOAJ Scopus

Background Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8+ T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigens…

Juga tersedia di: DOAJ

Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1‐specific CD8+ T cells

Frances E Pearson; Kirsteen M Tullett; Ingrid M Leal‐Rojas dkk.

Clinical & Translational Immunology, Vol. 9 No. 6 · 2020 · Inggris · DOAJ Scopus

Abstract Objectives Vaccines that prime Wilms' tumor 1 (WT1)‐specific CD8+ T cells are attractive cancer immunotherapies. However, immunogenicity and clinical response rates may be enhanced by delivering WT1 to CD141+ dendritic cells (DCs). The C‐type lectin‐like receptor CLEC9A is expressed…